CD BioGlyco is experienced in Recombinant Glycoprotein Vaccine development based on our professional R&D team. Arenavirus entry into cells is initiated by the viral envelope glycoprotein (GP). GP1 is located on the GP spines surrounding the virus and interacts with receptors on the plasma membrane of the host cell. GP2 is the transmembrane protein that anchors GP1 to the surface of the virus. They are important targets in the research of the process of viral infection and antiviral drugs. We offer subunit vaccines based on GP1 and GP2.
Fig.1 Structure of arenavirus. (Wikipedia)
We use molecular cloning technology to stably express GP1 and GP2 recombinant proteins through exogenous protein expression systems. Various expression systems are selected. Based on published viral gene sequences, viral target antigen genes are constructed recombinantly in expression vectors. The antigenic proteins are then transformed into Yeast, Mammalian, etc., and induced to be expressed. The vaccine is finally made by optimized purification methods.
This system uses of a shuttle plasmid as a vector to carry the target gene into the host strain and express the exogenous gene in the host strain. It has the characteristics of fast growth of prokaryotic expression strain, simple operation, and mass culture. It also has the advantage of post-translational processing and modification of exogenous genes. It achieves secretory expression of exogenous genes.
This system uses recombinant baculovirus vector that infects insect cells to express exogenous genes in the cells. After the recombinant baculovirus infects the insect cell, the exogenous gene is expressed under the initiation of the promoter. It also folds and modifies the translated protein.
It not only assembles and folds exogenous proteins correctly but also forms disulfide bonds, glycosylation modifications, etc. The proteins produced through this system are similar to those of natural structure.
Recombinant protein vaccines may have disadvantages such as lower immunogenicity and need to be used in conjunction with Adjuvants. We provide efficient adjuvant development services for arenavirus vaccines. We aim to find adjuvants that are safe and well-tolerated.
Fig.2 Process of arenavirus subunit vaccine development. (CD BioGlyco)
CD BioGlyco has been working for many years to provide glycan-related Vaccine development services for various viruses, including the Bunyaviridae virus, arenavirus, and others. We are ready to serve you at any time. All you need to do is contact us with your requirements. Our vaccine development team will complete all the experiments of design, synthesis, etc.
References
